AZN Stock Price Today (July 2026) — AstraZeneca PLC Analysis & Key Metrics 2026-07-17
AstraZeneca PLC (AZN) is trading at $168.90, down 0.23% today (as of July 2026). The stock continues to show pressure below major moving averages, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $224.49 (32.9% upside).
- Volatility remains elevated (39.99% annualized), implying wide price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (12.50% YoY) alongside significant competitive pressures.
AZN Stock Analysis: Key Metrics & Valuation (July 2026)
Concise, actionable data for investors
AstraZeneca PLC - Historical Price & Volume
Market Cap
Enterprise Value: $320.13B
P/E Ratio
Forward P/E: 24.07
Revenue Growth
Year over Year
Analyst Target
+32.9% upside potential
Key Investor Questions About AZN
What investors need to know before buying
Based on current market data, AZN presents a neutral technical setup with caution warranted fundamentals.
- Technicals say: Neutral (RSI 35.87)
- Fundamentals say: Caution warranted (high leverage concerns)
AZN's growth trajectory depends on its ability to expand within the Drug Manufacturers - General sector while managing margin pressures.
- Future growth will depend on performance in core Drug Manufacturers - General operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for AZN investors include debt exposure and competitive dynamics in the Drug Manufacturers - General industry.
- $34.03B in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Drug Manufacturers - General.
52-Week Trading Range
Over the past year, AZN stock traded between $137.22 and $212.71—recovering meaningfully from lows and currently near the higher end. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 39.99% annualized volatility and β=0.40, the stock exhibits low sensitivity to market moves—making AZN suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional backing, but elevated short interest signals a potential battleground stock.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
Cathie Wood Just Bet Big on This Biotech Stock
Ionis Pharmaceuticals' shares are down more than 27% so far this year. What does Cathie Wood see that others are missing?
Is NeoGenomics (NEO) Undervalued After Its FDA Approved PTEN Test Launch?
NeoGenomics (NEO) drew fresh attention after announcing PTEN IHC CDx, an FDA approved companion diagnostic that helps identify prostate cancer patients who may be eligible for AstraZeneca’s targeted therapy TRUQAP. See our latest analysis for NeoGenomics. The FDA-cleared PTEN IHC CDx arrives at a time when NeoGenomics’ share price has shown strong short term momentum, with a 30-day share price return of 40.75% and a 1-year total shareholder return of 134.13%, although the 3- and 5-year total...
The First Oral Cholesterol Pill Is Here. Which of These 5 Stocks Benefits Most?
The FDA just approved the first once-daily oral PCSK9 pill, and five major stocks now sit in the crosshairs. Not all of them come out ahead, and the biggest surprise winner may not be the company that makes the drug.
MSD wins FDA approval for cholesterol pill to help plug Keytruda void
MSD has outpaced rivals to market the first PCSK9 inhibitor in pill form for patients with high cholesterol.
Merck Stock Rises After U.S. Approval for Powerful Cholesterol-Cutting Pill
It’s the first pill that lowers blood cholesterol far better than statins, medicines that a quarter of adults take to reduce their risk of heart attack and stroke.
SLN Stock Skyrockets 107% in Six Months: Here's What You Need to Know
Silence Therapeutics shares surge as investors eye key 2026 divesiran data, an advancing RNAi pipeline and progress across multiple siRNA programs.
Attractive Growth Profile Positions AstraZeneca PLC (AZN) as Opportunity
Harris Oakmark recently released its second-quarter 2026 investor letter for the “Oakmark Global Fund”. A copy of the letter can be downloaded here. It is a non-diversified fund that focuses on long-term capital appreciation by investing in common stocks of U.S. and non-U.S. companies. In the second quarter, the fund (Investor Class) delivered a return of […]
AZN Inks Deal With Dizal to In-License Rights to Lung Cancer Drug
AstraZeneca is licensing Zegfrovy from Dizal in a deal worth up to $1.5B, expanding its lung cancer portfolio with a marketed EGFR therapy.
AstraZeneca (LSE:AZN) Secures Zegfrovy In $1.5 Billion Lung Cancer Licensing Deal
AstraZeneca has secured exclusive global rights to Dizal's Zegfrovy (sunvozertinib) through a new licensing agreement. Zegfrovy is an approved EGFR inhibitor for certain NSCLC patients with EGFR exon 20 mutations in the US and China. The deal adds an already commercialised lung cancer therapy to AstraZeneca's oncology portfolio and broadens its reach in key markets, including China. AstraZeneca (LSE:AZN) is adding a fresh commercial growth lever at a time when its shares are trading around...
Eli Lilly-Backed Novel Cancer Therapy Firm Raises $315 Million
(Bloomberg) -- AdvanCell Pty, a biotechnology firm backed by Eli Lilly & Co., has raised $315 million in new funding, underscoring investor confidence in its experimental cancer therapy.Most Read from BloombergThailand Scraps Plan to End Visa-Free Entry for Indian TouristsTrump Drops 20% Fee for Hormuz Cargo After Gulf PressureUS Hits Iran With Strikes, Blockade as Trump Plans Hormuz ChargeOpenAI’s First Device Will Be Movable, Screenless Speaker Built as AI Companion‘We Faltered’: IBM Plunges M
Frequently Asked Questions
Common investor questions about AstraZeneca PLC
AstraZeneca PLC (AZN) is currently trading at $168.90. The RSI (14-day) is at 35.9, indicating neutral territory. Wall Street analysts have a consensus "strong_buy" recommendation. The mean analyst price target of $224.49 implies 32.9% upside from current levels. Volatility is moderate at 40.0% annualized, meaning price movements are relatively contained. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for AstraZeneca PLC (AZN): The trailing P/E ratio is 25.44, which is in line with broader market averages. The forward P/E is 24.07, lower than the trailing P/E, suggesting analysts expect earnings improvement. The PEG ratio is 1.42, near 1.0, suggesting roughly fair value relative to growth. Price-to-Book is 5.53. Price-to-Sales is 4.33. Valuation should be compared to Drug Manufacturers - General industry peers for context, as different sectors trade at different multiples.
Based on 10 analysts covering AZN, the consensus price target is $224.49. This represents a 32.9% upside from the current price of $168.90. The range spans from a low target of $184.00 to a high target of $245.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "strong_buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Yes, AstraZeneca PLC (AZN) pays a dividend with a current yield of approximately 1.87%. The annualized dividend rate is $3.20 per share. The payout ratio is 47.7%, which is conservative and suggests the dividend is well-covered by earnings with room for future increases. The most recent ex-dividend date was 2026-02-20T00:00:00.000Z.
Key risks for AstraZeneca PLC (AZN) investors include: 1. Moderate volatility (40.0% annualized)—price swings are notable. 2. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 3. Drug Manufacturers - General sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is AstraZeneca PLC's (AZN) current debt and financial health profile: Total debt stands at $34.03B. The debt-to-equity ratio is 71.81, which is moderate and generally manageable for most companies. The current ratio is 0.91, which is below 1.0 and may indicate short-term liquidity concerns. The quick ratio is 0.70. The company holds $7.67B in cash and equivalents. Free cash flow is positive at $6.56B, providing a cushion for debt servicing and shareholder returns.